Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.72
ARIA's Cash to Debt is ranked lower than
83% of the 860 Companies
in the Global Biotechnology industry.

( Industry Median: 61.94 vs. ARIA: 0.72 )
Ranked among companies with meaningful Cash to Debt only.
ARIA' s 10-Year Cash to Debt Range
Min: 0.72  Med: 5.53 Max: 24.17
Current: 0.72
0.72
24.17
Equity to Asset -0.03
ARIA's Equity to Asset is ranked lower than
93% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ARIA: -0.03 )
Ranked among companies with meaningful Equity to Asset only.
ARIA' s 10-Year Equity to Asset Range
Min: -2.2  Med: 0.60 Max: 0.89
Current: -0.03
-2.2
0.89
F-Score: 5
Z-Score: -1.65
M-Score: -2.25
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -120.66
ARIA's Operating margin (%) is ranked lower than
56% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -71.14 vs. ARIA: -120.66 )
Ranked among companies with meaningful Operating margin (%) only.
ARIA' s 10-Year Operating margin (%) Range
Min: -526300  Med: -941.11 Max: 58.61
Current: -120.66
-526300
58.61
Net-margin (%) -127.42
ARIA's Net-margin (%) is ranked lower than
57% of the 677 Companies
in the Global Biotechnology industry.

( Industry Median: -67.10 vs. ARIA: -127.42 )
Ranked among companies with meaningful Net-margin (%) only.
ARIA' s 10-Year Net-margin (%) Range
Min: -493975  Med: -983.50 Max: 194.03
Current: -127.42
-493975
194.03
ROE (%) -277.87
ARIA's ROE (%) is ranked lower than
93% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -30.76 vs. ARIA: -277.87 )
Ranked among companies with meaningful ROE (%) only.
ARIA' s 10-Year ROE (%) Range
Min: -523.41  Med: -82.84 Max: 68.43
Current: -277.87
-523.41
68.43
ROA (%) -31.75
ARIA's ROA (%) is ranked lower than
54% of the 866 Companies
in the Global Biotechnology industry.

( Industry Median: -27.09 vs. ARIA: -31.75 )
Ranked among companies with meaningful ROA (%) only.
ARIA' s 10-Year ROA (%) Range
Min: -120.13  Med: -56.09 Max: 92.14
Current: -31.75
-120.13
92.14
ROC (Joel Greenblatt) (%) -78.94
ARIA's ROC (Joel Greenblatt) (%) is ranked higher than
62% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -390.34 vs. ARIA: -78.94 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ARIA' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3088.06  Med: -892.48 Max: 1083.41
Current: -78.94
-3088.06
1083.41
Revenue Growth (3Y)(%) 43.40
ARIA's Revenue Growth (3Y)(%) is ranked higher than
89% of the 412 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. ARIA: 43.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ARIA' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: -20.60 Max: 214.8
Current: 43.4
0
214.8
EBITDA Growth (3Y)(%) -4.70
ARIA's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ARIA: -4.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ARIA' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -16.2  Med: 4.80 Max: 36.2
Current: -4.7
-16.2
36.2
EPS Growth (3Y)(%) -2.20
ARIA's EPS Growth (3Y)(%) is ranked higher than
55% of the 418 Companies
in the Global Biotechnology industry.

( Industry Median: -6.80 vs. ARIA: -2.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ARIA' s 10-Year EPS Growth (3Y)(%) Range
Min: -18.1  Med: 0.50 Max: 24.7
Current: -2.2
-18.1
24.7
» ARIA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2014

ARIA Guru Trades in Q3 2014

Stanley Druckenmiller 1,645,000 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (-8.32%)
Jim Simons 1,252,681 sh (-71.53%)
George Soros 150,000 sh (-85.00%)
» More
Q4 2014

ARIA Guru Trades in Q4 2014

Paul Tudor Jones 27,227 sh (New)
Louis Moore Bacon 300,000 sh (unchged)
Chuck Royce 440,602 sh (unchged)
George Soros Sold Out
Stanley Druckenmiller Sold Out
Jim Simons 281,381 sh (-77.54%)
» More
Q1 2015

ARIA Guru Trades in Q1 2015

Joel Greenblatt 16,344 sh (New)
Michael Price 550,000 sh (New)
Jim Simons 2,675,481 sh (+850.84%)
Chuck Royce 375,352 sh (-14.81%)
Paul Tudor Jones 15,595 sh (-42.72%)
» More
Q2 2015

ARIA Guru Trades in Q2 2015

Michael Price 550,000 sh (unchged)
Chuck Royce 375,352 sh (unchged)
Joel Greenblatt Sold Out
Paul Tudor Jones 13,545 sh (-13.15%)
Jim Simons 2,094,481 sh (-21.72%)
» More
» Details

Insider Trades

Latest Guru Trades with ARIA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about ARIAD Pharmaceuticals Inc

Michael Price Invests in 11 Companies in First Quarter
Value investor Michael Price (Trades, Portfolio) is known for acquiring stock in out-of-favor small cap companies that are believed to be good values. His approach has paid off: Today, he manages MFP Investors, with $1.6 billion under management, much of it his own money. Read more...

Ratios

vs
industry
vs
history
P/S 10.52
ARIA's P/S is ranked lower than
56% of the 604 Companies
in the Global Biotechnology industry.

( Industry Median: 10.47 vs. ARIA: 10.52 )
Ranked among companies with meaningful P/S only.
ARIA' s 10-Year P/S Range
Min: 1.71  Med: 57.81 Max: 1334
Current: 10.52
1.71
1334
Current Ratio 3.30
ARIA's Current Ratio is ranked lower than
58% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.14 vs. ARIA: 3.30 )
Ranked among companies with meaningful Current Ratio only.
ARIA' s 10-Year Current Ratio Range
Min: 0.62  Med: 4.14 Max: 15.1
Current: 3.3
0.62
15.1
Quick Ratio 3.29
ARIA's Quick Ratio is ranked lower than
55% of the 837 Companies
in the Global Biotechnology industry.

( Industry Median: 4.00 vs. ARIA: 3.29 )
Ranked among companies with meaningful Quick Ratio only.
ARIA' s 10-Year Quick Ratio Range
Min: 0.52  Med: 4.03 Max: 14.95
Current: 3.29
0.52
14.95
Days Inventory 131.37
ARIA's Days Inventory is ranked lower than
54% of the 409 Companies
in the Global Biotechnology industry.

( Industry Median: 122.55 vs. ARIA: 131.37 )
Ranked among companies with meaningful Days Inventory only.
ARIA' s 10-Year Days Inventory Range
Min: 8.07  Med: 104.29 Max: 321.09
Current: 131.37
8.07
321.09
Days Sales Outstanding 39.06
ARIA's Days Sales Outstanding is ranked higher than
70% of the 570 Companies
in the Global Biotechnology industry.

( Industry Median: 62.77 vs. ARIA: 39.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
ARIA' s 10-Year Days Sales Outstanding Range
Min: 0.49  Med: 27.83 Max: 287.59
Current: 39.06
0.49
287.59

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.18
ARIA's Price/Median PS Value is ranked higher than
94% of the 542 Companies
in the Global Biotechnology industry.

( Industry Median: 1.07 vs. ARIA: 0.18 )
Ranked among companies with meaningful Price/Median PS Value only.
ARIA' s 10-Year Price/Median PS Value Range
Min: 0.02  Med: 0.46 Max: 19.2
Current: 0.18
0.02
19.2
Earnings Yield (Greenblatt) (%) -10.17
ARIA's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 823 Companies
in the Global Biotechnology industry.

( Industry Median: -6.10 vs. ARIA: -10.17 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ARIA' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -10.17  Med: 25.90 Max: 42.7
Current: -10.17
-10.17
42.7

Analyst Estimate

Dec15 Dec16 Dec17
Revenue(Mil) 141 185 285
EPS($) -1.16 -1.10 -0.65
EPS without NRI($) -1.16 -1.10 -0.65

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:0R2K.UK, ARIA.Switzerland, APS.Germany,
Ariad Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that they have developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
» More Articles for ARIA

Headlines

Articles On GuruFocus.com
Michael Price Invests in 11 Companies in First Quarter May 19 2015 
Sarah Ketterer of Causeway Capital's Answers to GuruFocus Q&A Apr 07 2014 
Weekly CEO Sells Highlight: U.S. Bancorp, Restoration Hardware Holdings Inc, Ariad Pharmaceuticals, Jul 20 2013 
Daniel Loeb's Top Three Increases of the First Quarter May 24 2013 
comment on ARIA Mar 15 2013 
comment on ARIA Mar 15 2013 
comment on ARIA May 16 2012 
Weekly CFO Sales Highlight: WWWW, FIO, CRIS, ARIA, VOG, APKT Apr 22 2012 
3 Biotech Stocks To Consider Buying Right Now Jan 10 2012 
ARIAD Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 

More From Other Websites
Overheard: Baxalta Shows Rare Deal Discipline Sep 02 2015
Word is the Ariad-Baxalta deal is dead. Here’s what we learned. Sep 02 2015
Baxalta Said to Quit Ariad Takeover Talks Sep 02 2015
Baxalta Said to Abandon Takeover Talks With Drugmaker Ariad Sep 02 2015
Biotech Stock Roundup: Amgen in the News, ARIAD a Takeover Target? Sep 02 2015
​Ariad is at the bottom of a big biotech food chain, at least for now Sep 01 2015
Mid-Afternoon Market Update: NASDAQ Down 1.3%; Medicines Company Shares Gain Following Announcement... Aug 31 2015
Ariad and Baxalta stay mum on merger reports, but speculation abounds Aug 31 2015
3 High-Volume Stocks to Trade Now (or Not) Aug 31 2015
Mid-Day Market Update: Crude Oil Surges 5.5%; ConforMIS Shares Tumble Aug 31 2015
ARIAD Skyrockets More than 40% Following Buyout Rumors Aug 31 2015
Ariad Pharmaceuticals (ARIA) Jumps: Stock Moves Up 41.7% Aug 31 2015
Baxalta makes $2bn move for rival after shunning Shire Aug 28 2015
The Top 3 Medtech Buyout Rumors This Week Aug 28 2015
Drugmaker Baxalta in talks to buy Ariad - Bloomberg Aug 28 2015
Initial Baxalta offer for Ariad rejected: Report Aug 28 2015
Baxalta in talks to buy Ariad: Report Aug 28 2015
ARIAD PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement Aug 21 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK